NSEOptions to purchase securities1d ago · 17 Nov 2026, 05:34 pm

Options to purchase securities

Nephrocare Health Services Limited · NEPHROPLUS

✦ AI Summaryoptions_to_purchase_securities

Nephrocare Health Services Limited has informed the Exchange about the grant of an aggregate of 38,236 Employee Stock Options under the NephroPlus Employee Stock Option Scheme, 2026, to eligible employees.

Analysis Scores

Earnings Impact2/10
Growth Catalyst1/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Nephrocare Health Services Limited has informed the Exchange about Options to purchase securities

Attachments (1)

📄

NEPHROCARE1_17112026173441_20261117_Reg_30_ESOP_Grant_of_Options_clean_signed.pdf

pdf

Download →
View document text
November 17, 2026 Ref: NEPHROPLUS/SE/103 To To BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, 5th Floor, Exchange Plaza, Bandra (E), Mumbai - 400 001 Mumbai - 400 051 Scrip Code: 544647 Scrip Symbol: NEPHROPLUS Through: BSE Listing Centre Through: NEAPS Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Grant of Employee Stock Options under NephroPlus Employee Stock Option Scheme, 2026. Dear Sir / Madam, Pursuant to Regulation 30 read with Para A of Part A of Schedule III and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform you that the Nomination and Remuneration Committee (“NRC”) of the Board of Directors of Nephrocare Health Services Limited (“the Company”), by way of a circular resolution passed on November 17, 2026, has approved the grant of an aggregate of 38,236 (Thirty- Eight Thousand Two Hundred and Thirty-Six only) Employee Stock Options (“Options”) under the NephroPlus Employee Stock Option Scheme, 2026 (“ESOP 2026”) to eligible employees identified by the NRC. Each Option, upon vesting and exercise in accordance with the terms and conditions of ESOP 2026 and the respective Grant Letters, shall entitle the Option Grantee to acquire one fully paid-up equity share of the Company having a face value of ₹2/- (Rupees Two only) each. The Options have been granted at an Exercise Price of ₹513.60 (Rupees Five Hundred Thirteen and Sixty Paise only) per Option and shall vest subject to fulfilment of the applicable vesting conditions, as specified in the respective Grant Letters. The relevant details with respect to the aforesaid grant, as required under the SEBI Listing Regulations read with SEBI Master Circular Ref. No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed as Annexure I. The aforesaid information is also being made available on the Company's website at www.nephroplus.com Yours faithfully, For Nephrocare Health Services Limited (Formerly Nephrocare Health Services Private Limited) Kishore Kathri Company Secretary and Head Legal Membership No.: F9895 Annexure I Details of grant of Employee Stock Options under the NephroPlus Employee Stock Option Scheme, 2026 Sr. Particulars Details 1 Brief details of Options The NRC has approved the grant of an aggregate of 38,236 granted (Thirty-Eight Thousand Two Hundred and Thirty-Six only) Employee Stock Options (“Options”) under ESOP 2026 to eligible employees of the Company. Each Option, upon vesting and exercise, shall entitle the Option Grantee to acquire one fully paid-up equity share of the Company having a face value of ₹2/- each. 2 Whether the Scheme is in Yes. ESOP 2026 is in compliance with the SEBI (Share Based terms of the SEBI (Share Employee Benefits and Sweat Equity) Regulations, 2021 (“SEBI Based Employee Benefits SBEB Regulations”). and Sweat Equity) Regulations, 2021 3 Total number of shares 38,236 equity shares of face value of ₹2/- each may arise upon covered by these Options exercise of the Options, assuming vesting and exercise of all Options granted. Each Option is convertible into one equity share of the Company. 4 Pricing formula / Exercise The Options have been granted at an Exercise Price of ₹513.60 Price (Rupees Five Hundred Thirteen and Sixty Paise only) per Option, as determined by the NRC in accordance with ESOP 2026 and specified in the respective Grant Letters. 5 Options vested Not applicable at this stage. The Options granted are subject to a minimum vesting period of one year from the Grant Date and fulfilment of the applicable Vesting Conditions and other terms specified in the respective Grant Letters. 6 Time within which The Vested Options may be exercised within a maximum period Options may be exercised of 5 (five) years from the date of each respective Vesting, or within such shorter period as may be prescribed by the NRC and specified in the relevant Grant Letter, subject to the terms and conditions of ESOP 2026. In the event of cessation of employment/service or other specified events, the Exercise Period shall be governed by the applicable provisions of ESOP 2026. 7 Options exercised Not applicable at this stage. 8 Money realised by Not applicable at this stage. exercise of Options 9 Total number of shares Not applicable at this stage. arising as a result of exercise of Options 10 Options lapsed Not applicable at this stage. 11 Variation of terms of Not applicable at this stage. Options 12 Brief details of significant The Options shall be governed by ESOP 2026, the respective terms Grant Letters and the SEBI SBEB Regulations, and shall vest subject to the fulfilment of the applicable vesting conditions as approved by the NRC and set out in the respective Grant Letters, as accepted by the Option Grantees. The Options shall, in all circumstances, be subject to the applicable minimum vesting period prescribed under ESOP 2026 and applicable law. 13 Subsequent changes or Not applicable at this stage. cancellation or exercise of such Options 14 Diluted earnings per Not applicable at this stage. share pursuant to issue of equity shares on exercise of Options